Evaluation of Droplet Digital PCR Rapid Detection Method and Precise Diagnosis and Treatment for Suspected Sepsis

Sponsor
Huashan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05190861
Collaborator
(none)
2,000
9
2
18
222.2
12.3

Study Details

Study Description

Brief Summary

Sepsis is a significant public health concern worldwide, with high morbidity and mortality. With regard to a targeted antimicrobial treatment strategy, the earliest possible pathogen detection is of crucial importance. Until now, culture-based detection methods represent the diagnostic gold standard, although they are characterized by numerous limitations. Culture-independent molecular diagnostic procedures may represent a promising alternative. In particular, droplet digital PCR (ddPCR) is a novel one-step PCR assay that achieves higher accuracy and sensitivity in detecting causing pathogens in patients with bloodstream infections.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: droplet digital PCR method
  • Diagnostic Test: blood culture
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of Droplet Digital PCR Rapid Detection Method and Precise Diagnosis and Treatment for Suspected Sepsis
Actual Study Start Date :
Nov 29, 2021
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: droplet digital PCR method

Pathogen detection by droplet digital PCR method as an adjunct to traditional microbiological assessments including blood culture

Diagnostic Test: droplet digital PCR method
The droplet digital PCR method can detect nucleic acids from the most common pathogens (approximately 90%) responsible for BSIs according to Chinet2020 and takes about 4 hours to perform, reporting within the first 24h of suspected sepsis/septic shock.

Active Comparator: blood culture only

Pathogen detection by microbiological assessments including blood culture

Diagnostic Test: blood culture
Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling.

Outcome Measures

Primary Outcome Measures

  1. Sensitivity [Up to 96 hours post blood collection]

    The primary endpoint of estimated sensitivity will be determined by comparing positive blood culture results with the concomitantly collected ddPCR results from the prospective clinical specimens.

  2. Specificity [Up to 96 hours post blood collection]

    The primary endpoint of estimated specificity will be determined by comparing negative blood culture results with the concomitantly collected ddPCR results from the prospective clinical specimens.

Secondary Outcome Measures

  1. Time to the change to the targeted antimicrobial therapy [At time point of change to the targeted antimicrobial therapy, up to 96 hours post blood collection]

  2. Number of patients with targeted antimicrobial therapy [Up to the end of study participation, an average of 1 year]

  3. Time to identification of a potential pathogen [At time point of identification of a potential pathogen, up to 96 hours post blood collection]

  4. Duration of antimicrobials [Up to the end of study participation, an average of 1 year]

  5. Change in condition severity [Up to the end of study participation, an average of 1 year]

    The sequential organ failure assessment score (SOFA score), previously known as the sepsis-related organ failure assessment score, higher scores mean worse outcome.

  6. Days in intensive care unit (ICU) [Up to the end of study participation, an average of 1 year]

  7. Ventilation duration in ICU (hours) [Up to the end of study participation, an average of 1 year]

  8. Days in hospital (from study inclusion) [Up to the end of study participation, an average of 1 year]

  9. All-cause death [Up to the end of study participation, an average of 1 year]

  10. Treatment costs [Up to the end of study participation, an average of 1 year]

  11. Quality of life of survivors after being discharged [Up to the end of study participation, an average of 1 year]

    EQ-5D, a standardised measure of health-related quality of life developed by the EuroQol Group.The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The number of levels in these dimensions is 5 in the EQ-5D-5L. Higher levels mean worse health states.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

1.18 years or older

2.Meet 2 of 4 sepsis criteria

  1. Temperature > 38C or < 36C

  2. Heart rate > 90 bpm

  3. Respiratory rate >20 or PaCO2 <32mmHg

  4. WBC >12000/µL or < 4000/µL or > 10% bands

3.Hospitalized patients who have a diagnostic blood culture ordered as standard of care for suspected sepsis

4.Informed Consent by patient or legal representative.

Exclusion Criteria:
  1. Refusal to participate in the study or Failure to comply with treatment or follow-up time

  2. Known breastfeeding or pregnancy

  3. The researcher believes that there are any conditions (social or medical) that allow subjects to participate is unsafe. For example, severe anemia or high risk of bleeding,etc., which are not suitable for taking peripheral blood for testing

  4. Participating in other clinical studies

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affiliated Hospital of Anhui Medical University Hefei Anhui China 230022
2 Xiangya Hospital Central South University Changsha Hunan China 410013
3 Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine Nanjing Jiangsu China 210001
4 Wuxi No.5 People's Hospital Wuxi Jiangsu China 214016
5 Xinhua Hospital Affliated to Shanghai Jiao Tong University School of Medicine Shanghai Shanghai China 200092
6 Shanghai Sixth People's Hospital Shanghai Shanghai China 200233
7 Minhang Branch of Ruijin Hospital Shanghai Shanghai China 201100
8 Zhejiang Rui'an People's Hospital Rui'an Zhejiang China 325200
9 The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China 325000

Sponsors and Collaborators

  • Huashan Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wen-hong Zhang, Director of Division of Infectious Diseases, Huashan Hospital
ClinicalTrials.gov Identifier:
NCT05190861
Other Study ID Numbers:
  • PROGRESS
First Posted:
Jan 13, 2022
Last Update Posted:
Jan 13, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wen-hong Zhang, Director of Division of Infectious Diseases, Huashan Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 13, 2022